Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.92 USD | -1.75% | -7.71% | +37.30% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.30% | 273M | |
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals : Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q4 Revenue $23.6M